Navigation Links
Digirad Corporation Reports Financial Results for First-Quarter 2008
Date:4/24/2008

e U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.

Investor Contact: Company Contact:

Dan Matsui Todd Clyde, CFO

Allen & Caron 858-726-1600

949-474-4300 ir@digirad.com

Digirad Corporation

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended

March 31,

2008 2007

Revenues:

DIS $13,854 $12,197

Product 4,417 5,341

Total revenues 18,271 17,538

Cost of revenues:

DIS 10,912 8,938

Product 2,946 3,158

Total cost or revenues 13,858 12,096

Gross profit 4,413 5,442

Operating expenses:

Research and development 644 782

Sales and marketing 2,119 2,098

General and administrative 3,159 2,972

Amort
'/>"/>

SOURCE Digirad Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Digirad Corporation to Release First Quarter Financial Results on April 24, 2008
2. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
3. Digirad Corporation to Release Fourth Quarter, Year-End Financial Results on February 7, 2008
4. Digirad to Introduce New Clinical Standard for Cardiac SPECT
5. Digirad Corporation Board of Directors Appoints R. King Nelson Chairman
6. Digirad Corporation and The Methodist Hospital in Houston Sign Letter of Agreement
7. Digirad Reports 2007 Third-Quarter, Nine-Month Financial Results
8. Digirad Corporation Named to Deloitte Technology Fast 50
9. Digirad Corporation to Release Third Quarter, Nine-Month Financial Results on October 25, 2007
10. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
11. STERIS Corporation Declares Regular Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... ... “ reTXT ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... any message including ones already sent. , While text messaging has more features than ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
(Date:7/31/2015)... ... ... Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award winner ... reduction in New York. Due to its unparalleled level of experience for these ... travel to New York to get their non-surgical skin tightening and body shaping procedures ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Sculpted Contours ... the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the ... January 2014 for treating the outer thighs. The original applicator required a 2 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... , , , MINNEAPOLIS, ... and marketer of state-of-the-art cardiac surgery products and services, today reported financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ) , , Second ... or 17.0% higher than the second quarter of 2008. Revenue from ...
... CRANBURY, N.J., Aug. 3 Innophos Holdings, Inc. (Nasdaq: ... financial results for the second quarter 2009. , , ... Net sales for the second quarter 2009 were $166.8 million, ... the same period in 2008. Selling price increases had a positive effect ...
... , , SAN DIEGO, Aug. ... financial results for the second quarter ended June 30, 2009. , ... in the second quarter of 2009 of $38.0 million, or $0.48 per share, ... of 2008 of $65.8 million, or $0.89 per share, and a net loss ...
... , , BIRMINGHAM, Ala., Aug. 3 ... reports Operating Income of $50.4 million, or $1.52 per diluted share for ... million, or $1.62 per diluted share. For the six months ended June ... and Net Income was $82.2 million, or $2.46 per diluted share. , ...
... NEW YORK, Aug. 3 The uninsured issue has become a ... are currently without health insurance, a number that is continuing to ... large hospitals and clinics for sick visits and emergencies -- as ... patients arrive at hospitals and clinics, by State law, the facility ...
... a good time with friends, researchers say, , MONDAY, Aug. ... why one in 10 high school seniors have tried opioid ... reasons included relaxation, feeling good or getting high, experimentation and ... hydrocodone, oxycodone, hydromorphone, meperidine, morphine and codeine without a prescription, ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Results 2Health News:ATS Medical Announces Second Quarter 2009 Results 3Health News:ATS Medical Announces Second Quarter 2009 Results 4Health News:ATS Medical Announces Second Quarter 2009 Results 5Health News:ATS Medical Announces Second Quarter 2009 Results 6Health News:ATS Medical Announces Second Quarter 2009 Results 7Health News:ATS Medical Announces Second Quarter 2009 Results 8Health News:ATS Medical Announces Second Quarter 2009 Results 9Health News:ATS Medical Announces Second Quarter 2009 Results 10Health News:ATS Medical Announces Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 2Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 3Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 4Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 5Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 6Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 7Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 8Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 9Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 10Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 11Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 12Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 13Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 14Health News:Innophos Holdings, Inc. Reports Second Quarter 2009 Results 15Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 2Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 3Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 4Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 5Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 6Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 7Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 8Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 9Health News:Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments 10Health News:ProAssurance Reports Second Quarter 2009 Results 2Health News:ProAssurance Reports Second Quarter 2009 Results 3
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Oct. 7 /PRNewswire-Asia/ -- ... ... var ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Oct. 7 Marine biotechnology specialist Azantis, Inc ... to its clients, in an effort to provide continued ... an agreement with SafetyCall International , Azantis has ... and Post-Market Surveillance services. SafetyCall medical ...
Cached Medicine Technology:Professor Steven V. Ley Speaks at WuXi PharmaTech 2Professor Steven V. Ley Speaks at WuXi PharmaTech 3Professor Steven V. Ley Speaks at WuXi PharmaTech 4Professor Steven V. Ley Speaks at WuXi PharmaTech 5Professor Steven V. Ley Speaks at WuXi PharmaTech 6Professor Steven V. Ley Speaks at WuXi PharmaTech 7Azantis Announces New Consumer Safety Program 2
Vaulted shank with guard....
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
... head design has been carefully considered with both ... head ensures the optimum viewing angle and the ... laser aligned for perfect focus where it is ... paper. This along with Keeler's wide angle ...
The Beta 200S combines Heine's patented aspherical optics (U.S. Pat. 4.963.014) and a single-step Rekoss disk with a range of 36 to +38 dpt. to provide perfectly-focused images even in cases of high ...
Medicine Products: